[The impact of antidepressive therapy on work productivity and life satisfaction--a one-year follow-up study].
OBJECTIVE
One of the most frequent causes of temporary or permanent diminution of work productivity is depression. The complete recovery of depression means fully restored creativity, work production and life satisfaction. Antidepressive treatment is regarded effective if besides symptom remission, the original functions and roles are fully restored, i.e. life satisfaction significantly improves. The aim of this study was to assess the improvement of work productivity and life satisfaction of paroxetin treated depressives.


METHODS
The study was a 52 weeks lasting open, multicentric, self-controlling survey with the inclusion of 1407 paroxetin treated depressed patients. Apart from recording demographic data, comorbidities, course of the illness, and scales measuring the severity of the illness (HAMD, CGI-S, CGI-I), scales indicating the impairment of work productivity (SAS, SDS) and life satisfaction (LS) were also processed.


RESULTS
Besides the improvement of the depressive symptoms (HAMD scores decreased from 22.6 to 3.8; and CGI-S scores from 4.7 to 1.3), the scores of work productivity and life satisfaction also significantly decreased (SAS scores from 2.8 to 1.3, SDS scores from 18.2 to 2.8, and LS scores from 14.9 to 7.1, respectively). Following the acute treatment period, work productivity and life satisfaction further continuously improved till the end of the maintenance treatment phase.


CONCLUSIONS
Parallel to the improvement of the depressive symptoms, the number of absence days decreased, the work performance, free time activity and family functioning significantly improved. A significant correlation was found between the improvement of depressive symptoms and the positive changes in work production and life satisfaction.
Fabian
Zsolt
Z
Országos Pszichiátriai és Neurológiai Intézet, I. Pszichiátriai Osztály.
Karányi
Zsolt
Z
Szádóczky
Erika
E
D000328:Adult; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D015897:Comorbidity; D003866:Depressive Disorder / Q000188:drug therapy / Q000523:psychology*; D004526:Efficiency / Q000187:drug effects*; D004651:Employment; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017374:Paroxetine / Q000627:therapeutic use*; D010549:Personal Satisfaction; D011358:Product Surveillance, Postmarketing; D011446:Prospective Studies; D011788:Quality of Life; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014937:Work
D018687:Antidepressive Agents, Second-Generation; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors